1924-P: Continuous Glucose Monitoring (CGM) in Non-ICU Medical and Surgical Wards: Pilot Study on Feasibility, Glycemic Outcomes, and Discharge Transition

Introduction and Objective: CGM is an emerging tool for inpatient diabetes care despite limited published data. Within a structured pathway, we evaluated the clinical feasibility of FreeStyle Libre 3 Plus sensor (FSL3+), the first CGM approved for in hospital use, and its utility in optimizing glycemic outcomes during hospitalization and after discharge. Methods: We conducted a retrospective, single-center pilot study of 30 insulin-treated adults with diabetes admitted to non-ICU medical and surgical wards. FSL3+ was applied during hospitalization and continued at home until the first outpatient consultation, planned within 30 days. We assessed CGM glycemic outcomes and feasibility/safety across prespecified inpatient (first vs last 48 h) and post-discharge (14 days before follow-up) time windows. Paired differences were primarily assessed with the Wilcoxon signed-rank test. Results: We analyzed 30 consecutive inpatient CGM users (T1D n=1, T2D n=29; age 66.7±12.2 y; BMI 29.6±5.6 kg/m²; HbA1c 71.7±25.9 mmol/mol). Median length of stay was 9.0 d (IQR 6.0-13.8) and sensor wear 7.0 d (5.0-13.0). Glycemic control improved significantly from the first to the last 48 h of hospitalization: TIR increased from 57.0% (32.5-72.0) to 71.5% (60.0-78.5) (p<0.01), TITR (70-140) increased from 25.0% (6.0-44.8) to 42% (28.8-48.8) (p<0.01), TAR decreased from 41.0% (26.0-67.5) to 26.0% (21.0-36.8) (p<0.01) and TBR remained < 2.2%. Most hypoglycemic events occurred overnight (69.8%), without severe episodes. CGM enabled proactive remote follow-up every 28±12 h, with 2.8±1.3 therapy adjustments/patient, mainly prompted by CGM alerts reported by ward staff. Post-discharge TIR was 71.0% (64.0-87.0), suggesting maintenance of glycemic control. Conclusion: In non-ICU setting, the use of FSL3+ was feasible, tolerated and associated with improved glycemic outcomes highlighting its utility within a structured discharge transition. Disclosure F. Di Marco: None. A. Rossi: Consultant; Ended; Roche Diabetes Care, Abbott Diabetes. J. Bertini: Advisory Panel; Ended; Abbott. A. Pedroli: None. G. Guabello: None. M. Ben Nasr: None. M.E. Lunati: None. P. Fiorina: Board Member; Ended; Novo Nordisk, Lilly, AstraZeneca, Boehringer Ingelheim International GmbH.